Literature DB >> 23764764

Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years.

G Moroni1, S Quaglini, B Gallelli, G Banfi, P Messa, C Ponticelli.   

Abstract

Whether the long-term patient and renal survival of those diagnosed with lupus nephritis (LN) has improved over the decades is still debated. Eighty-nine patients diagnosed between 1968 and 1990 entered this study and their outcome was evaluated after 20 years. At presentation 54% of patients had class IV LN, 39.3% had renal insufficiency and 59.5% had nephrotic syndrome. Patients were divided into two groups: Group 1 consisted of 30 patients diagnosed between 1968 and 1980; Group 2 consisted of 59 patients diagnosed between 1981 and 1990. In Group 1 patient survival at 20 years was 84% versus 95% in Group 2 (p=0.05). Survivals without end-stage renal failure were respectively 75% and 84% at 20 years (p=0.05). Survivals without severe infection at 20 years were 44% in Group 1 and 66.5% in Group 2 (p=0.02). Survivals without cardiovascular events at 20 years were: 53% in Group 1 and 90% in Group 2 (p=0.005). At presentation, patients in Group 1 had higher serum creatinine (1.96 vs 1.15 mg/dl, p=0.01), higher activity index (8 vs 5.5, p=0.01), lower hematocrit (31% v s6%, p=0.008) and lower serum C4 levels (p=0.04) than Group 2 patients. Patients in Group 1 also received less frequent methylprednisolone pulses (43% vs 81%, p=0.0006). In Italian patients with LN, long-term life expectancy and renal survival progressively improved over the decades, while morbidity progressively declined. An earlier referral and refinement of therapy achieved this goal.

Entities:  

Keywords:  Lupus patient survival; immunosuppressive therapy; lupus nephritis; lupus renal survival; methylprednisolone pulses; systemic lupus erythematosus

Mesh:

Substances:

Year:  2013        PMID: 23764764     DOI: 10.1177/0961203313492576

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Clinicopathological and outcome analysis of adult lupus nephritis patients in China.

Authors:  Yi Tang; XiaoYan Zhang; Ling Ji; XuHua Mi; Fei Liu; LiChuan Yang; Wei Qin
Journal:  Int Urol Nephrol       Date:  2015-01-07       Impact factor: 2.370

2.  Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-04       Impact factor: 8.237

3.  Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013.

Authors:  Titilola Falasinnu; Marios Rossides; Yashaar Chaichian; Julia F Simard
Journal:  Public Health Rep       Date:  2018-06-21       Impact factor: 2.792

Review 4.  Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.

Authors:  Maria G Tektonidou; Abhijit Dasgupta; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995

5.  A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.

Authors:  John G Hanly; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; M A Dooley; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Susan Manzi; Ola Nived; Gunnar K Sturfelt; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

6.  Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.

Authors:  Yoshiya Tanaka; Tsutomu Takeuchi; Nobuyuki Miyasaka; Takayuki Sumida; Tsuneyo Mimori; Takao Koike; Kazuhiro Endo; Naomi Mashino; Kazuhiko Yamamoto
Journal:  Mod Rheumatol       Date:  2015-08-19       Impact factor: 3.023

7.  The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis.

Authors:  Stephen M Korbet; William L Whittier; Edmund J Lewis
Journal:  Nephron Extra       Date:  2016-08-18

8.  Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort.

Authors:  Xuebing Feng; Wenyou Pan; Lin Liu; Min Wu; Fuwan Ding; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Lingyun Sun
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

9.  Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.

Authors:  Antonio Fernández-Nebro; Íñigo Rúa-Figueroa; Francisco J López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Carmen Ordóñez-Cañizares; María A Martín-Martínez; Ricardo Blanco; Rafael Melero-González; Jesús Ibáñez-Rúan; José Antonio Bernal-Vidal; Eva Tomero-Muriel; Esther Uriarte-Isacelaya; Loreto Horcada-Rubio; Mercedes Freire-González; Javier Narváez; Alina L Boteanu; Gregorio Santos-Soler; José L Andreu; José M Pego-Reigosa
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

10.  Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.

Authors:  Alexandra Audemard-Verger; Nicolas Martin Silva; Céline Verstuyft; Nathalie Costedoat-Chalumeau; Aurélie Hummel; Véronique Le Guern; Karim Sacré; Olivier Meyer; Eric Daugas; Cécile Goujard; Audrey Sultan; Thierry Lobbedez; Lionel Galicier; Jacques Pourrat; Claire Le Hello; Michel Godin; Rémy Morello; Marc Lambert; Eric Hachulla; Philippe Vanhille; Guillaume Queffeulou; Jacky Potier; Jean-Jacques Dion; Pierre Bataille; Dominique Chauveau; Guillaume Moulis; Dominique Farge-Bancel; Pierre Duhaut; Bernadette Saint-Marcoux; Alban Deroux; Jennifer Manuzak; Camille Francès; Olivier Aumaitre; Holy Bezanahary; Laurent Becquemont; Boris Bienvenu
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.